Journal: Cancer Medicine

Article Title: STEAP1 Suppresses Oral Squamous Cell Carcinoma by Targeting Wnt/β‐Catenin Signalling and EMT

doi: 10.1002/cam4.71862

Figure Lengend Snippet: STEAP1 Effect on the wnt/β‐catenin signalling pathway in OSCC cell lines. (A–J) The effect of STEAP1 on the wnt/β‐catenin signalling pathway in SAS and Tca‐8113 cells was assessed and quantitatively analysed by Western Blot. (* p < 0.05, ** p < 0.01, **** p < 0.0001).

Article Snippet: China); a mouse anti‐human β‐actin antibody (TA‐09, ZSBIO, China); a rabbit anti‐human P‐GSK‐3β antibody (BM4837, BOSTER, China); a rabbit anti‐human GSK‐3β antibody (A00791‐3, BOSTER, China); a rabbit anti‐human β‐catenin antibody (PA1212, BOSTER, China); primary rabbit anti‐human c‐Myc antibody ( T55150 , Abmart, China); primary rabbit anti‐human Axin2 antibody ( R23574 , ZENBIO, China); secondary goat anti‐mouse IgG antibody (ZB2305, ZSBIO, China); secondary goat anti‐rabbit IgG antibody (ZB2301, ZSBIO, China).

Techniques: Western Blot

Journal: bioRxiv

Article Title: Bacterial internalins exploit E-cadherin to promote head and neck tumor metastasis and drug resistance

doi: 10.64898/2026.04.20.719623

Figure Lengend Snippet: (A-B) β-catenin localization in TIGK cells treated with InlB (A) or InlA (B) for 2 h or overnight was assessed by immunofluorescence microscopy. Ctrl: PBS. Scale bars: 20 μm. (C) Immunoblot analysis of cytoplasmic and nuclear β-catenin levels in TIGK cells following overnight InlB treatment. Ctrl: PBS. (D) Immunoblot analysis of β-catenin phosphorylation in TIGK cells treated with InlB for 2 h or overnight. Ctrl: PBS.

Article Snippet: Primary antibodies used in this study include anti-His (Invitrogen, cat. no. MA1-21315); E-cadherin (R&D Systems, cat. no. AF648); β-catenin (R&D Systems, cat. no. MAB1329); AKT (Cell Signaling Technology, cat. no. 9272); phospho-AKT (Ser473; cat. no. 9271); p38 (cat. no. 9212); phospho-p38 (Thr180/Tyr182; cat. no. 9211); JNK (cat. no. 9252); phospho-JNK (Thr183/Tyr185; cat. no. 9251); NF-κB p65 (cat. no. 8242); phospho-NF-κB p65 (Ser536; cat. no. 3033); c-Jun (cat. no. 9165); phospho-c-Jun (Ser63; cat. no. 9164); ERK1/2 (cat. no. 9102); phospho-ERK1/2 (Thr202/Tyr204; cat. no. 4370); and β-actin (cat. no. 3700) (all from Cell Signaling Technology unless otherwise indicated).

Techniques: Immunofluorescence, Microscopy, Western Blot, Phospho-proteomics

Journal: bioRxiv

Article Title: Bacterial internalins exploit E-cadherin to promote head and neck tumor metastasis and drug resistance

doi: 10.64898/2026.04.20.719623

Figure Lengend Snippet: InlA and InlB bind E-cadherin, triggering β-catenin stabilization and nuclear translocation, which induces EMT transcription factors (Slug, Twist, ZEB1) and MMP9, promoting metastasis. Concurrently, internalin-E-cadherin engagement activates downstream ROCK, p38 and JNK MAPK signaling, attenuating cisplatin-induced apoptosis through upregulation of Bcl-2 and suppression of Bax, ultimately conferring chemoresistance. These coordinated pathways mechanistically link P. gingivalis infection to cancer progression and therapeutic resistance. Green arrows denote activation; red blocked arrows denote inhibition.

Article Snippet: Primary antibodies used in this study include anti-His (Invitrogen, cat. no. MA1-21315); E-cadherin (R&D Systems, cat. no. AF648); β-catenin (R&D Systems, cat. no. MAB1329); AKT (Cell Signaling Technology, cat. no. 9272); phospho-AKT (Ser473; cat. no. 9271); p38 (cat. no. 9212); phospho-p38 (Thr180/Tyr182; cat. no. 9211); JNK (cat. no. 9252); phospho-JNK (Thr183/Tyr185; cat. no. 9251); NF-κB p65 (cat. no. 8242); phospho-NF-κB p65 (Ser536; cat. no. 3033); c-Jun (cat. no. 9165); phospho-c-Jun (Ser63; cat. no. 9164); ERK1/2 (cat. no. 9102); phospho-ERK1/2 (Thr202/Tyr204; cat. no. 4370); and β-actin (cat. no. 3700) (all from Cell Signaling Technology unless otherwise indicated).

Techniques: Translocation Assay, Infection, Activation Assay, Inhibition